Goldman Sachs analyst, Jami Rubin, reiterated his Buy rating on shares of Abbvie (NYSE: ABBV) after the company announced that ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE